An Innovative Phase 2 Proof-of-Concept Trial Design to Evaluate SAR445088, a Monoclonal Antibody Targeting Complement C1s in Chronic Inflammatory Demyelinating Polyneuropathy.

Luis Querol,Richard A Lewis,Hans-Peter Hartung,Pieter A Van Doorn,Erik Wallstroem,Xiaodong Luo,Miguel Alonso-Alonso,Nazem Atassi,Richard A C Hughes

Journal of the peripheral nervous system : JPNS（2023）

引用 1|浏览16

暂无评分

摘要

This innovative trial design based on patient groups and Bayesian statistics provides an efficient paradigm to evaluate new candidate treatments across the CIDP spectrum and can help accelerate development of new therapies. This article is protected by copyright. All rights reserved.

查看译文

关键词

Bayesian analysis, CIDP, complement classical pathway, complement C1s, SAR445088, trial design

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要